The DOI matches its Crossref record; 112 of the 114 references it cites were found in a registry or an index.
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
Open accessAbstract
The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinically, GLP-1 RAs are indicated for the treatment of type 2 diabetes (all) and obesity (liraglutide and semaglutide only) and have beneficial effects on patient-important outcomes such as weight loss, cardiovascular and kidney events, hepatic steatosis, and mortality.5,7–9,11,30”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“By contrast, modern treatment guidelines for type 2 diabetes 154 and essential hypertension 155 (also nutrition related chronic diseases), do recommend a stepped care approach to pharmacotherapy.”
From Effectiveness and safety of drugs for obesity (2024) · cites this paper as [154]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“As a result, GLP-1 RAs are contraindicated for patients with a personal or family history of MTC or those with multiple endocrine neoplasia syndrome type 2.8,17,22”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredIn the citing paper
“However, a 5% weight reduction is insufficient to improve many aspects of health, and greater weight losses confer greater benefits, 23,82,83 with some data suggesting that there may be a threshold effect for reduction in some important comorbidities such as CVD and diabetes remission.[84][85][86]”
From Approach to Obesity Treatment in Primary Care: A Review (2024) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Self-citationRiddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 1,039
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Self-citation
Flagged first, then by citations
2 of the 114 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
Cited by
Sorted by citations
Items 801–852 of 852
Csatordai, M., Benkő, R., Matúz, M., Engi, Z., Csupor, D., Lengyel, C., & Doró, P. (2024) · Figshare · doi:10.6084/m9.figshare.26711591
Wang, P., Zhang, Y., Xu, W., He, J., Peng, L., Feng, Y., Xu, P., Chong, W., Hai, Y., Jia, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24940868
González-Vidal, T., Rivas‐Otero, D., Gutiérrez-Hurtado, A., Felgueroso, C. A., Tamés, G. M., Lambert, C., Delgado, E., & Torre, E. L. M. (2023) · Figshare · doi:10.6084/m9.figshare.24719239
Wang, P., Zhang, Y., Xu, W., He, J., Peng, L., Feng, Y., Xu, P., Chong, W., Hai, Y., Jia, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26659708
Csatordai, M., Benkő, R., Matúz, M., Engi, Z., Csupor, D., Lengyel, C., & Doró, P. (2024) · Figshare · doi:10.6084/m9.figshare.26711588
Ono, R., Ogami, C., Hasegawa, C., To, H., Matsumoto, Y., & Tsuji, Y. (2023) · Figshare · doi:10.6084/m9.figshare.24779192
Gu, X., Jiang, S., Yang, Y., & Li, W. (2024) · Figshare · doi:10.6084/m9.figshare.24987804
Peng, Z.-Y., Yang, C.-T., Lin, W.-H., Yao, W.-Y., Ou, H.-T., & Kuo, S. (2024) · Figshare · doi:10.6084/m9.figshare.26623015
Yu, M., Wang, R., Pei, L., Zhang, X., Wei, J., Wen, Y., Liu, H., Ye, H., Wang, J., & Wang, L. (2024) · Figshare · doi:10.6084/m9.figshare.26606593
Chronische Niereninsuffizienz bei Typ-2-Diabetes – die stille Bedrohung einer Multisystemerkrankung
Günes-Altan, M., & Schmieder, R. (2025) · Diabetes aktuell · doi:10.1055/a-2624-4700
Winberg, D., Xuan, D., Tang, T., Marchi, N., & Shi, L. (2025) · Pharmacoeconomics and Policy · doi:10.1016/j.pharp.2025.09.002
Glucose is a ligand-like trigger for secretion of postprandial GLP-1Preprint
Li, C. M., Li, M., Yang, H.-Y., Tian, X., Zhang, C., Zhao, L., Wu, J., Zhang, C., Liu, S., Yang, X., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.04.697549
Wu, C.-Y., Lai, C., Ho, C., Wu, Y.-C., Liao, K., Wang, J.-J., Wang, D.-C., & Liang, F. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/1437417 · Cited by 1
Xian, X., Chen, J., Li, Z., Zheng, Q., Lei, X., Bai, C., Zhang, Y., & Fu, G. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1683063
Li, Y., Chen, J., Gao, Y., Zhang, J., Deng, S., Li, H., Zhang, X., & Li, R. (2026) · Diabetes Therapy · doi:10.1007/s13300-025-01836-2
SEA 2026 Standards for Global Control of Vascular Risk
Mostaza, J. M., Pintó, X., Armario, P., Guijarro, C., Masana, L., Real, J. T., Arrobas-Velilla, T., Baeza‐Trinidad, R., Calmarza, P., Cebollada, J., et al. (2026) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2026.500889
Bariatric surgery in the era of modern obesity pharmacotherapy
Zhao, A. Y., & Dash, S. (2026) · Obesity and Endocrinology · doi:10.1093/obendo/wjag004
Hass, D., Madsen, A. N., da Silva‐Buttkus, P., Kjølbye, A. L., Støy, S. H., Nøhr-Meldgaard, J., Sandahl, T. D., de Angelis, M. H., Jørgensen, R., Rohm, M., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.041
Sarwal, A., Throolin, M. J., Wei, G., Nevers, M. R., Hartsell, S. E., Shen, J., Boucher, R. E., & Beddhu, S. (2026) · Primary care diabetes · doi:10.1016/j.pcd.2026.04.004
Campbell, I. W., Brand, K. M. G., Gottwald‐Hostalek, U., & Dettenbach, J. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03592-6
Desai, N. R., Inzucchi, S. E., & Wright, E. E. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01856-6
Wang, V. H.-C., Sabboor, S. A., Xu, J., Rajbhandari, J., Hall, D. B., Shi, L., Lau, R., Chen, X., Young, H. N., Wang, S., et al. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.03.015
A study of prescribing pattern in type-1 and type-2 diabetes in a tertiary care centre
Patil, S. B., Baig, M. S., & Bhattacharya, M. (2026) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20261335
Depression Associated with Other Medical Conditions
Sunzeri, F., & Sunzeri, E. (2026) · Springer eBooks · doi:10.1007/978-3-032-14465-2_12
Analyzing longitudinal antidiabetic medication patterns: a data-driven clustering framework
Zhang, P., Mason, J. E., Sohn, M., Hallal, P. C., & Kang, H. (2026) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-026-03539-5
Choi, Y. S., Jeon, J., Baik, M., Yoo, J., & Kim, J. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70341
Roh, W.-L., Shin, W., Yoo, H., Ahn, K. H., Lee, Y., & Kim, A. (2026) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-026-01014-0
GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists
Abid, M., Sheikh, K. S., Ahmad, M. S., & Jiang, H. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s566414
Actividad física en la diabetes de tipo 2
Duclos, M. (2026) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(26)51956-1
Tu, Y.-K., Liang, Y.-C., Wu, Y.-J., Hung, K.-C., Yu, T., Lai, C., Chen, C.-C., & Wu, J. (2026) · Medicine · doi:10.1097/md.0000000000049365
Lee, C. C., & Liu, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45863-7.00086-x
He, B.-B., & Wu, G.-Y. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-06162-4
Modular Approach on Implementing a Type 1 Diabetes-Mellitus Simulator
Palko, N. R., Berciu, A.-G., Kovács, L., & Dulf, E. H. (2026) · IEEE International Conference on Automation, Quality and Testing, Robotics (AQTR) · doi:10.1109/aqtr70159.2026.11577941
Xiao, Y. R., shen, L., Song, Y., Liu, Y., Xin, Y. Z., Luo, Y., Zhang, Q. J., Zhang, W., Wang, X., Zhang, X., et al. (2026) · Intensive Care Medicine Experimental · doi:10.1186/s40635-026-00940-2
Stanetić, K., Bajagić, S., Vujnović, S., & Stanetić, М. (2026) · Respiratio · doi:10.5937/respira2602015s
Characterization of a polysaccharide from Ipomoea batatas and its in vitro hypoglycemic activity
Ma, L., Hou, F., Dai, W.-W., Yang, X., Yang, K., Bi, Y., Li, Z. Y., Yuan, B., & Zhang, L. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.153580
Noureldine, H. A., Abraham, A., Mojaddedi, S., Alqudah, Q., Gill, A. S., & Tong, A. T. (2026) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2026.6.e24
Shen, D., Xiong, H., Deng, G., Jiang, X. Y., & Zeng, Q. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02427-3
An antisense oligonucleotide targeting STK25 as a long-acting therapeutic candidate for early MASLD
Dong, A., Li, N., Lang, X., Chen, S., Qin, Y., Wang, Y., Wang, H., Guo, M., Yan, A., Song, K., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103038 · Cited by 1
Arvez, M. J. A., Wade, S., Goordeen, D., Ilomäki, J., Cross, A. J., Langiu, M., & Tan, G. S. Q. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70414
Agarwal, S., Basit, M. A., MARBLE, K., Mai, C., Bowen, M. E., Pak, J., Elnakieb, Y. A., & Lingvay, I. (2026) · Primary care diabetes · doi:10.1016/j.pcd.2026.07.015
Attività fisica nel diabete di tipo 2
Duclos, M. J. (2026) · EMC - AKOS - Trattato di Medicina · doi:10.1016/s1634-7358(26)52113-2
Mahmoud, N. M., Hussein, A., Mussa, B. M., & Abusnana, S. (2026) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514261471399
Cardiometabolic drugs after stroke: time to embrace SGLT2 inhibitors and incretin-based therapies?
Ihle‐Hansen, H., Ihle-Hansen, H., Blauenfeldt, R. A., Dawson, J., Diederichsen, S. Z., & Hagberg, G. (2026) · Frontiers in Stroke · doi:10.3389/fstro.2026.1918465
Chen, E.-L., & Kocis, P. T. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.00209-8
Mavridis, A., Abzhandadze, T., Buvarp, D., Simons, K., Eliasson, B., von Euler, M., Viktorisson, A., & Sunnerhagen, K. S. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104220
Fuller, Z., Singh, M., Dawar, A., Thomas, J., Daniels, A. H., & Abdo, Z. E. (2026) · Journal of Orthopaedic Experience & Innovation · doi:10.60118/001c.162883
Gonzalez‐Cruz, D., García-Campa, M., Moreno-Peña, P. J., Ávalos‐Bishop, A., Manzanares-Gallegos, D. M., García, F. M. G., Montiel-Labastida, J. A., González‐González, J. G., Agarwal, A., Manja, V., et al. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2026-002780
SAGES surgical management of gastroparesis: systematic review and expert consensus
Calabrese, E., Shehata, D. G., Kumar, S., Marom, G. A., Chan, C., Chandrasekar, N., Galvani, C. A., Kurian, M. S., Vierra, M. A., Akram, I., et al. (2026) · Surgical Endoscopy · doi:10.1007/s00464-026-13411-2
Devi, A. A., Pavani, B., Bhanu, K., Khan, M. T., & Kumari, D. V. R. (2026) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20263767
Su, Y.-C., Li, B. M., Cheng, M. C., Lin, Y., & Lai, E. C. (2026) · Medicina · doi:10.3390/medicina62112068
Metadata
- Authors
- ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Khunti, K., Leon, J., Lyons, S. K., Perry, M. L., Prahalad, P., Pratley, R. E., Seley, J. J., Stanton, R. C., & Gabbay, R. A.
- ORCID
- ElSayed, Nuha A.
- Aleppo, Grazia
- Aroda, Vanita R.
- Bannuru, Raveendhara R.
- Brown, Florence M.
- Bruemmer, Dennis
- Collins, Billy S.
- Hilliard, Marisa E.
- Isaacs, Diana
- Johnson, Eric L.
- Kahan, Scott
- Khunti, Kamlesh
- Lyons, Sarah K.
- Perry, Mary Lou
- Prahalad, Priya
- Pratley, Richard E.
- Seley, Jane Jeffrie
- Stanton, Robert C.
- Gabbay, Robert A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-12-12
- Volume
- 46
- Issue
- Supplement_1
- Pages
- S140-S157
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC9810476
- OpenAlex
- W4311264067
- Semantic Scholar
- f75bf88f7fa4c4c0cf940dad739ba96bb6d15d64
- Cited by
- 851
- References
- 114
- Citations by year
- 2026: 64 · 2025: 149 · 2024: 360 · 2023: 277 · 2022: 1
- FWCI
- 28.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, diabetes mellitus, antidiabetic drugs, clinical guidelines, treatment goals, quality of care
- MeSH terms
- Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
